Skip to main content
. 2020 Apr 1;124(6):693–701. doi: 10.1016/j.bja.2020.01.030

Fig. 1.

Fig. 1

Flow of participants showing eligibility, recruitment, protocol deviations, withdrawals, and loss to follow-up in the REVAKI-2 trial. CKD, chronic kidney disease; CYP3A4, cytochrome P450 3A4; eGFR, estimated glomerular filtration rate; NAION, non-arteritic anterior ischaemic optic neuropathy; RRT, renal replacement therapy.